Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New therapeutic properties of N-acetyl-L-cysteine discovered

19.01.2009
Researchers from the Department of Biochemistry and Molecular Biology at the Univesidad de Alcalá (UAH), confirm that N-acetyl-L-cysteine (NAC) combined with mesalamine produces a significant improvement in patients suffering from ulcerative colitis.

The team headed by Luis González Guijarro, biochemistry and molecular biology professor at the UAH, in collaboration with the pharmaceutical firm Farmasierra S.L., has developed a pilot study of the effects of N-acetyl-L-cysteine on patients suffering from moderate or mild ulcerative colitis.

The conclusion reached in this study, and published in the World Journal of Gastroenterology, is that the association of N-acetyl-L-cysteine and mesalamine, reduces the symptoms of patients affected with this condition. Previous to now, these patients were treated solely with mesalamine.

Professor González Guijarro explains that ulcerative colitis is a form of inflammatory bowel disease that specifically affects the colon, producing free radicals and hydrogen peroxide. The cells of our immune system protect the body from infections using several weapons and neutrophils, the most abundant type of white blood cell in our organism, destroying microorganisms and producing hydrogen peroxide. Hydrogen peroxide is unstable and breaks down into hydroxyl radicals that cause damage to the delicate tissues. Professor González Guijarro states that the intention of the co-administration of NAC and mesalamine was to eliminate the hydrogen peroxide and reduce the number of free radicals using N-acetyl-L-cysteine. N-acetyl-L-cysteine is a precursor to glutathione, a molecule that along with glutathione peroxidase, eliminates hydrogen peroxide.

The study carried out in collaboration with the Gregorio Marañón hospital and the Princesa hospital, is the first step in the long process that has to take place before any drug reaches drugstores. Work must begin on the association of mesalamine and NAC into a single product; since the study was carried out by administering one drug as a pill and the other as a soluble compound.

The professor of biochemistry and molecular biology insists that the clinical and biochemical effects have to be continuously recorded in order to corroborate the preliminary indications. For example, that this association does not produce any adverse side effects, and that N-acetyl-L-cysteine can be significant in the quimioprevention of colon cancer.

Another objective of the team of the UAH is to direct the molecule to the inflamed colon, using an enteric coating that should degrade at a certain pH. This way when the patient ingests the pill, the drug will pass through the stomach and intestine and will only be released in the colon.

N-acetyl-L-cysteine, is a drug normally used for the treatment of chronic obstructive pulmonary disease (COPD) and to minimize the effects of cold and flu. Its hepatic protective properties also make this drug a useful tool in paracetamol intoxications.

The research team at Alcalá University has been studying the new therapeutic properties of NAC for years, producing results such as an in vitro study where N-acetyl-L-cysteine reduced the negative effects caused by azathioprine, a immunosuppressant of clinical use, on the liver. Currently many research groups are working on the application of NAC in the treatment of diverse pathologies, such as diabetes, alcohol and cocaine dependence syndromes.

Every advance in the treatment of ulcerative colitis is of great relevance because the disease causes many discomforts in the patient while conditioning their life. In the early stages the symptoms are mainly diarrhea, weight loss, and intestinal bleeding, but once it aggravates, intestinal fistulas appear. “Nowadays new extremely powerful drugs are being developed; so-called biological drugs, like anti-TNF antibodies, that even manage to cure the fistulas but cause negative side effects and are very expensive. Every improvement in the application of classic drugs with enteric coatings, combinations of drugs, etc… represent less risk for the patient and savings for the social security” states González Guijarro.

“The future in treating diseases is customized treatments. In order for a drug to work, the weight and age of the patient must be considered, but their genetic information will also provide the key to evaluate whether a certain molecule would be effective for the particular patient” concludes the Professor of the UAH.

Oficina de Información Cien | alfa
Further information:
http://www.uah.es

More articles from Life Sciences:

nachricht Bioenergy cropland expansion could be as bad for biodiversity as climate change
11.12.2018 | Senckenberg Forschungsinstitut und Naturmuseen

nachricht How glial cells develop in the brain from neural precursor cells
11.12.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

Im Focus: Substitute for rare earth metal oxides

New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals

Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.

Im Focus: A bit of a stretch... material that thickens as it's pulled

Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.

Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

Electronic evidence of non-Fermi liquid behaviors in an iron-based superconductor

11.12.2018 | Physics and Astronomy

Topological material switched off and on for the first time

11.12.2018 | Materials Sciences

NIST's antenna evaluation method could help boost 5G network capacity and cut costs

11.12.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>